Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 17, 2026
Reporting period
Not applicable
Filed with the SEC
Feb 18, 2026
CEOOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001140361-26-005888
Filed / recorded
Feb 18, 2026, 2:39 AM UTC
Added to OQRO
Oct 6, 2026, 9:54 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ADMA BIOLOGICS, INC.
Issuer CIK
1368514
Ticker
ADMA
Reporting person
Adam S Grossman
Relationship
Director, Officer
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 17, 2026
Transaction code
M
Shares / units
15,000
Price per share
$5.40
Acquired / disposed
Acquired (A)
Shares owned after
2,305,379
Ownership form
Direct
Amendment
No
Footnotes from the filing
Transaction was effected pursuant to a Rule 10b5-1 trading plan entered into between the Reporting Person and Fidelity Brokerage Services LLC on November 14, 2025.